Omeros Corp. Stock
€5.37
Your prediction
Omeros Corp. Stock
Pros and Cons of Omeros Corp. in the next few years
Pros
Cons
Performance of Omeros Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omeros Corp. | -8.520% | -4.533% | 52.297% | 33.982% | -51.839% | 93.514% | -44.248% |
| Ardelyx Inc. | 1.480% | 4.175% | 16.856% | 12.450% | 1.511% | 311.563% | 2.983% |
| Krystal Biotech | 1.570% | 2.484% | 8.107% | 3.942% | 15.210% | 133.800% | - |
| Evolus Inc | 0.000% | 0.826% | 12.963% | -46.018% | -41.905% | -13.475% | 107.695% |
Comments
News
Breakout Momentum Plays You Need to Know About
Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Shares of Omeros (NASDAQ: OMER) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.
It was a deal with the Danish
Omeros Posts 2,652 Percent Sales Jump
Omeros (NASDAQ:OMER), a biopharmaceutical company focused on developing treatments for rare diseases and immune-related conditions, released its second quarter results on August 14, 2025. The


